The 1st international conference on innovative solutions in the treatment of GERD in pediatric patients held in Croatia – Alkaloid AD as one of the torchbearers of innovations for sustainable and resilient health systems!
astroesophageal Reflux Disease, or GERD, affects countless children worldwide, disrupting sleep, nutrition, and overall well-being. Managing GERD in pediatric patients extends beyond medication—it’s a multifaceted challenge involving healthcare policies, accessibility, education, and long-term support.
First International Conference on Modern Approaches to GERD Treatment in Pediatric Patients „REINVENTING PEDIATRIC GERD CARE“ delved into the complexities of pediatric GERD care, posing critical questions: What barriers exist in current healthcare systems, from access to unmet needs? How can we enhance treatment outcomes and improve adherence of pediatric patients? What can we do to accelerate access of value added medicines and implement reforms in shaping a better future for young patients?
A groundbreaking development is reshaping the treatment landscape- Alkaloid AD Skopje has introduced the world’s first ready-to-use liquid omeprazole, specifically designed for children who struggle with swallowing traditional tablets. This innovative formulation is ensuring better adherence and comfort for young patients- resulting with clinical, human and economic benefits.
Awarded the 2023 Patent of the Year, this value-added medicine exemplifies how innovation can directly address patient needs, particularly in pediatric care.
This international conference explored the transformative potential of such innovations in pediatric GERD care, examining how they intersect with policy, technology, and patient education to improve outcomes and adherence.
By introducing innovative approach in generic industry, and supporting this multidisciplinary scientific event, Alkaloid AD has again highlighted the value and contribution of the pharmaceutical industry in thinking outside the box when it comes to sustainable health systems, emphasizing that the post-pandemic period requires a partnership of all stakeholders in building sustainable and resilient health systems, which, within limited financial resources, should ensure access to innovations with maximum economic, clinical and human benefit.
Photo by Alkaloid
“Alkaloid” opens new horizons in the treatment of GERD with liquid omeprazole
As the holder of the first international patent for a value-added medicine – Omeprazole in liquid form: ready to use – “Alkaloid” was the sponsor of the First International Conference on Modern Approaches to the Treatment of GERD in Pediatric Patients, organized in Zagreb, Croatia.
More than 200 healthcare professionals from the fields of pediatrics, gastroenterohepatology, nutrition, pharmacy and pharmacology experts, academics, and Alkaloid representatives participated in the first global event under the auspices of the company dedicated to the latest advances in the treatment of gastroesophageal reflux disease (GERD) in infants and young children. The event focused on the first patented liquid Omeprazole, an innovation that brings significant improvements in the pediatric treatment of this common condition.
Omeprazole belongs to the group of proton pump inhibitors and is a first-line therapy in the treatment of GERD, traditionally available in the form of gastro-resistant tablets, capsules or powder for dissolution, which makes its use difficult in infants older than one month, young children, patients with swallowing difficulties, patients with gastric feeding tubes, as well as in geriatric patients. “Alkaloid” for the first time in history managed to develop omeprazole in a patented liquid form, enabling a new, practical and effective approach to the treatment of these sensitive groups of patients.
Zhivko Mukaetov, General Director and Chairman of the Board of Directors of Alkaloid
Photo by Alkaloid
“This product highlights Alkaloid’s commitment to top achievements in the pharmaceutical field and sets new standards in generic drug production, with a focus on innovation and market differentiation. Alkaloid’s innovative value-added drug is already opening new horizons in the treatment of GERD in pediatric patients, primarily in terms of the availability of therapy, which was not previously the case, showing positive results in the treatment of these sensitive groups of patients and improving the quality of life of families facing this common disease,” noted Zhivko Mukaetov, General Director and Chairman of the Board of Directors of Alkaloid.
Photo by Alkaloid
Following patenting in September 2023, liquid Omeprazole was first launched in February 2024 on the markets in Macedonia and the United Kingdom, and this international conference was an excellent opportunity to exchange clinical experiences, as well as to share good practices and innovative approaches in pediatric practice. Healthcare professionals from Macedonia, the United Kingdom, Belgium, Slovenia, Croatia, Bosnia and Herzegovina, Bulgaria, Romania, Serbia and Kosovo discussed the challenges they face in the treatment of GERD, as well as the benefits of introducing this innovative formulation of Omeprazole, pointing to its efficacy, safety and improved tolerability in the youngest patients.
A team of experts from various fields at Alkaloid worked for 6 years on the development of liquid Omeprazole. The innovative concept of this medicine includes a two-chamber disposable bottle, which separately contains two solutions – one with a high pH and one diluent. By mixing the solutions immediately before use, a stable formulation with an optimal pH value is obtained, which protects the active substance from degradation upon contact with gastric acid, enabling appropriate, safe and effective application of the therapy in pediatric patients, as well as in other sensitive groups of patients. To meet the specific requirements in the production process of this medicine, Alkaloid invested in a purpose-built machine, suitable for this innovative product, ensuring an efficient and sustainable supply chain around the world.
Omeprazole solution is available on the markets of Macedonia, the United Kingdom, Ireland, Romania and Croatia. The product is currently in the process of obtaining marketing authorization in several other countries.
“Innovations in pharmaceutical technology, such as liquid omeprazole, are coming from our region and they are an indicator of how the generic industry can also think very innovatively, ensuring that drugs that have been used for many years are available to patients in a form that is focused on the patient and their better adherence. In doing so, Alkaloid AD ensures a direct contribution to the sustainability of healthcare systems so that existing therapeutic options are in favor of the patient and much easier, regular application of prescribed therapy, while improving their compliance and treatment outcomes, without complications and deterioration that would further burden the hospital (and healthcare system in general).”
Photo by Alkaloid
Alkaloid AD as one of the torchbearers of innovations for sustainable and resilient health systems!
Innovations in pharmaceutical technology, such as liquid omeprazole, are coming from our region and they are an indicator of how the generic industry can also think very innovatively, ensuring that drugs that have been used for many years are available to patients in a form that is focused on the patient and their better adherence. In doing so, Alkaloid AD ensures a direct contribution to the sustainability of healthcare systems so that existing therapeutic options are in favor of the patient and much easier, regular application of prescribed therapy, while improving their compliance and treatment outcomes, without complications and deterioration that would further burden the hospital (and healthcare system in general).
This is the model we should consider for the future in which healthcare systems and industry is using existing molecules in an innovative way with innovative technology, in order to ensure the allocation of saved resources towards needed innovations. Alkaloid AD is truly is one of the torchbearers of such an approach!
“This is the model we should consider for the future in which healthcare systems and industry is using existing molecules in an innovative way with innovative technology, in order to ensure the allocation of saved resources towards needed innovations. Alkaloid AD is truly is one of the torchbearers of such an approach!”
Photo by Freepik
REFERENCES //
https://alkaloid.com.mk/alkaloid-opens-new-horizonts
You may also like
